Utilizing TP53 mutation status and initial disease burden at presentation to risk-stratify patients with advanced EGFR-mutated NSCLC treated with osimertinib.
Authors: Chetan Vakkalagadda, Briana Lee, Jacob Alex, Shauna Rakshe, Jessica Minnier, Jeremy Paul Cetnar